Hydrophilic agarose macrobead cultures select for outgrowth of carcinoma cell populations that can restrict tumor growth

Cancer Research

Volumn 71, Issue 3, 2011, Pages 725-735

  Smith, Barry H ^a,c   Gazda, Lawrence S ^a,e   Conn, Bryan L ^e   Jain, Kanti ^a,e   Asina, Shirin ^e   Levine, Daniel M ^a   Parker, Thomas S ^a   Laramore, Melissa A ^e   Martis, Prithy C ^e   Vinerean, Horatiu V ^e   David, Eric M ^a   Qiu, Suizhen ^a   North, Alison J ^d   Couto, C Guillermo ^f   Post, Gerald S ^h   Waters, David J ⁱ   Cordon Cardo, Carlos ^b   Hall, Richard D ^g   Gordon, Bruce R ^a,c   Diehl, Carolyn H ^a   Stenzel, Kurt H ^a   Rubin, Albert L ^a   more..

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d ROCKEFELLER UNIVERSITY   (United States)

^e ROGOSIN INSTITUTE   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g Bob Evans Farms Inc   (United States)

^h Veterinary Oncology and Hematology Center   (United States)

ⁱ Gerald P Murphy Cancer Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; FIBULIN; GELSOLIN; NUCLEOLIN; OSTEONECTIN; PEROXIREDOXIN 1; PHOSPHATIDYLETHANOL AMINE BINDING PROTEIN 1; PIGMENT EPITHELIUM DERIVED FACTOR; PROSAPOSIN; SERPINE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL ENCAPSULATION; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; EPITHELIUM; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MALE; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ANIMALS; CARCINOMA, RENAL CELL; CELL CULTURE TECHNIQUES; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; HCT116 CELLS; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; SEPHAROSE; SPECIES SPECIFICITY;

EID: 79551543920     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2258     Document Type: Article

References (50)

1. Smith BH, Gazda LS, Conn BL, Jain K, Asina S, Levine DM, et al. Three-dimensional culture of a mouse renal adenocarcinoma line in agarose macrobeads selects for a subpopulation of cells with cancer stemcell or cancer progenitor properties. Cancer Res 2011;71:716-24.
2. Laird AK. Dynamics of tumour growth: comparison of growth rates and extrapolation of growth curve to one cell. Br J Cancer 1965;19:278-91.
3. Laird AK, Tyler SA, Barton AD. Dynamics of normal growth. Growth 1965;29:233-48.
4. Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature 1976;264:542-5.
5. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res 1988;48:7067-71.
6. NortonL.Cancer stemcells, self-seeding, anddecrementedexponential growth: theoretical and clinical implications. Breast Dis 2008;29:27-36.
7. Speer JF, Petrosky VE, Retsky MW, Wardwell RH. A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 1984;44:4124-30.
8. De Wys WD. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 1972;32:374-49.
9. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989;49:1996-2001. (Pubitemid 19106503)
10. Weedon-Fekjaer H, Lindqvist BH, Vatten LJ, Aalen OO, Tretli S. Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res 2008;10:R41.
11. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50.
12. Hemmings C. The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis. Pathology 2010;42:105-12.
13. Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991;51:2-4.
14. Jain K, Cai BR, Patel S, Yang H, Smith BH, Suthanthiran M, et al. Consistent long-term allograft survival in murine pancreatic islet transplants without immunosuppression. Transplant Proc 1994;26:3492-3.
15. Jain K, Yang H, Asina SK, Patel SG, Desai J, Diehl C, et al. Long-term preservation of islets of Langerhans in hydrophilic macrobeads. Transplantation 1996;61:532-6. (Pubitemid 26073594)
16. Jain K, Asina S, Yang H, Blount ED, Smith BH, Diehl CH, et al. Glucose control and long-term survival in biobreeding/Worcester rats after intraperitoneal implantation of hydrophilic macrobeads containing porcine islets without immunosuppression. Transplantation 1999;68:1693-700.
17. Gazda LS, Adkins H, Bailie JA, Byrd W, Circle L, Conn B, et al. The use of pancreas biopsy scoring provides reliable porcine islet yields while encapsulation permits the determination of microbiological safety. Cell Transplant 2005;14:427-39.
18. Jain K, Yang H, Cai BR, Haque B, Hurvitz AI, Diehl C, et al. Retrievable, replaceable, macroencapsulated pancreatic islet xenografts. Longterm engraftment without immunosuppression. Transplantation 1995;59:319-24.
19. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med 1992;326:1335-41.
20. Tanaka M, Mullauer L, Ogiso Y, Fujita H, Moriya S, Furuuchi K, et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 1995;55:3228-32.
21. Walsh N, Dowling P, O'Donovan N, Henry M, Meleady P, Clynes M. Aldehyde dehydrogenase 1A1 and gelsolin identified as novel invasion-modulating factors in conditioned medium of pancreatic cancer cells. J Proteomics 2008;71:561-71.
22. Gay F, Estornes Y, Saurin JC, Joly-Pharaboz MO, Friederich E, Scoazec JY, et al. In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma. Hum Pathol 2008;39:1420-30.
23. Xie L, Palmsten K, MacDonald B, Kieran MW, Potenta S, Vong S, et al. Basement membrane derived fibulin-1 and fibulin-5 function as angiogenesis inhibitors and suppress tumor growth. Exp Biol Med 2008;233:155-62. (Pubitemid 351231547)
24. Srivastava M, Fleming PJ, Pollard HB, Burns AL. Cloning and sequencing of the human nucleolin cDNA. FEBS Lett 1989;250:99-105.
25. Shi H, Huang Y, Zhou H, Song X, Yuan S, Fu Y, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007;110: 2899-906.
26. O'Brien JS, Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 1991;5:301-8.
27. Kang SY, Halvorsen OJ, Gravdal K, Bhattacharya N, Lee JM, Liu NW, et al. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci U S A 2009;106:12115-20.
28. Abe R, Fujita Y, Yamagishi S, Shimizu H. Pigment epithelium-derived factor prevents melanoma growth via angiogenesis inhibition. Curr Pharm Des 2008;14:3802-9.
29. Ek ET, Dass CR, Choong PF. PEDF: a potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 2006;12:497-502.
30. Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med 2007;85:15-22.
31. Filleur S, Nelius T, de Riese W, Kennedy RC. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem 2009;106:769-75.
32. Chen SC, Henry DO, Hicks DG, Reczek PR, Wong MK. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. J Urol 2009;181:336-42.
33. Chen SC, Henry DO, Reczek PR, Wong MK. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol Cancer Ther 2008;7:1227-36.
34. Romer MU, Larsen L, Offenberg H, Brunner N, Lademann UA. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia 2008;10:1083-91.
35. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001;159:609-22.
36. Dhanesuan N, Sharp JA, Blick T, Price JT, Thompson EW. Doxycycline- inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Res Treat 2002;75:73-85.
37. DiMartino JF, Lacayo NJ, Varadi M, Li L, Saraiya C, Ravindranath Y, et al. Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia 2006;20:426-32.
38. Esposito I, Kayed H, Keleg S, Giese T, Sage EH, Schirmacher P, et al. Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia 2007;9:8-17.
39. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, DeClerck YA. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994;54:5467-73.
40. Seo DW, Li H, Guedez L, Wingfield PT, Diaz T, Salloum R, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003;114:171-80.
41. Stetler-Stevenson WG, Seo DW. TIMP-2: an endogenous inhibitor of angiogenesis. Trends Mol Med 2005;11:97-103.
42. Hagan S, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, et al. Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. Clin Cancer Res 2005;11:7392-7.
43. Schuierer MM, Bataille F, Hagan S, Kolch W, Bosserhoff AK. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res 2004;64:5186-92.
44. Akaishi J, Onda M, Asaka S, Okamoto J, Miyamoto S, Nagahama M, et al. Growth-suppressive function of phosphatidylethanolamine-binding protein in anaplastic thyroid cancer. Anticancer Res 2006;26:4437-42.
45. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 2006;131:1208-17.
46. Granovsky AE, Rosner MR. Raf kinase inhibitory protein: a signal transduction modulator and metastasis suppressor. Cell Res 2008;18:452-7.
47. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003;424:561-5.
48. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, et al. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. Embo J 2009;28:1505-17.
49. Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, et al. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases. Prostate 2000;45:173-83.
50. Vlasin M, Rauser P, Fichtel T, Necas A. Subtotal intracapsular prostatectomy as a useful treatment for advanced-stage prostatic malignancies. J Small Anim Pract 2006;47:512-6. (Pubitemid 44327613)